Hospital-acquired Infection Treatment Market Global Demand Analysis & Opportunity Outlook 2026 | Pfizer Inc., Bayer AG, GlaxoSmithKline Plc., Daiichi Sankyo Company Limited

Hospital-acquired infections can be extremely distressing for patients who are already ailing through an existing condition. The growing use of surgical equipment, or treatment aids, that are often unsterilized has increased the incidence of hospital-acquired infections. Treatment of these infections is crucial to ensure that the recovery cycle of patients doesn't get disrupted. Nosocomial site infection is the most common hospital-acquired infection that has gained traction from the healthcare fraternity.

It is important to administer pragmatic treatment lines to prevent or alleviate the incidence of healthcare-acquired infections (HAIs) infections. In view of the aforementioned factors, it is safe to state that the global hospital-acquired infection treatment market would tread along a lucrative trajectory.

Get a Sample Copy of the Hospital-acquired Infection Treatment Market: https://www.fairfieldmarketresearch.com/report/hospital-acquired-infection-treatment-market/request-sample

The collective implications of acquiring infections during surgery are abysmal. Patients who acquire such infections are five times more likely to require readmission to hospitals post discharge. Moreover, these patients spend, on an average, 6.5 extra days in the hospital as against a normal recovering patient. The healthcare industry is taking cognizance of these trends to assimilate treatment frameworks that prioritize the prevention of infections. Several practices such as the use of robotic surgery and treatment systems to reduce HAIs could emerge across the healthcare industry in the times to follow.

Key Players: Global Hospital-acquired Infection Treatment Market

1. Merck & Co. Inc.
2. Pfizer Inc.
3. Bayer AG
4. GlaxoSmithKline Plc.
5. Daiichi Sankyo Company Limited
6. AbbVie Inc.
7. F. Hoffmann-La Roche Ltd
8. Allergan Plc.
9. Bristol-Myers Squibb
10. AstraZeneca
11. Cepheid
12. Johnson & Johnson Services Inc.
13. Cipla Inc.
14. DAIICHI SANKYO COMPANY LIMITED
15. GlaxoSmithKline plc.

High Incidence of Urinary Tract Infections to Bolster the Prospects of Market Growth

Several types of hospital-acquired infections have irked healthcare professionals in recent years. Some of these infections include pneumonia, nosocomial infections, bloodstream infections, and urinary tract infections. Amongst these, the incidence of urinary tract infection is estimated to be the highest amongst patients of varying age groups. In the US, urinary tract infections account for 32% of all hospital-acquired infections. The rising costs associated with treatment of such infections has led the healthcare industry to rethink its modes of treatment and disease prevention. HAIs incur heavy expenditures upon the healthcare industry, and could be a source of turmoil within global healthcare. It is, therefore, logical to expect a rise in investments towards treating hospital-acquired infections.

Do You Have Any Query Or Specific Requirement? Request Customization of Report: https://www.fairfieldmarketresearch.com/report/hospital-acquired-infection-treatment-market/request-customization

Asia Pacific Market Exhibits a Humongous Opportunity for Market Growth and Expansion

Several developing countries in Asia Pacific are characterized by poorly-managed primary healthcare units (PHUs). Therefore, the incidence of hospital acquired infections in the region is alarmingly high. However, renewed efforts of state bodies to rejuvenate the healthcare setup in the region offers a commendable opportunity for market growth and expansion. The casualty count owing to HAIs is exceedingly high across India. This factor is also necessitating the use of effective treatment lines to alleviate the impacts of hospital acquired infections. The second wave of the COVID-19 pandemic almost toppled the healthcare industry in India, and necessitated the development of a robust framework to prevent secondary infections. This factor shall bode well for the growth of the Asia Pacific hospital acquired infection treatment market.

Trending Reports by Fairfield Market Research-

Vehicle Battery Market: https://www.electronicsmedia.info/2022/04/21/vehicle-battery-market-awaits-upbeat-growth-prospects/

Pigments Market: https://www.coatingsworld.com/contents/view_breaking-news/2022-04-18/fairfield-market-research-global-pigments-market/

Lithium Mining Market: https://www.power-and-beyond.com/lithium-mining-market-set-for-staggering-performance-through-2025-a-1018871/

Hemophilia Treatment Market: https://www.globenewswire.com/en/news-release/2022/05/10/2439938/0/en/Hemophilia-Treatment-Market-is-Expected-to-be-Reach-US-21-349-6-Million-by-2027-at-a-Healthy-Pace-of-5-2-CAGR-Fairfield-Market-Research.html

Contact
Fairfield Market Research
London, UK
UK +44 (0)20 30025888
USA +1 (844) 3829746 (Toll-free)
Email: sales@fairfieldmarketresearch.com
Web: https://www.fairfieldmarketresearch.com/
Follow Us: https://bit.ly/3voYIm9

About Us :-
Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values and eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.

This release was published on openPR.